Showing posts with label virus. EHDV. Show all posts
Showing posts with label virus. EHDV. Show all posts

Wednesday, September 22, 2010

Manufacturing Biologics with CHO Cells? What’s the Risk for Viral Contamination?

by Dr. Ray Nims

Chinese hamster ovary (CHO) cells are frequently used in the biopharmaceutical industry for the manufacture of biologics such as recombinant proteins, antibodies, peptibodies, and receptor ligands. One of the reasons that CHO cells are often used is that these cells have an extensive safety track record for biologics production. This is considered to be a well-characterized cell line, and as a result the safety testing required may be less rigorous in some respects (e.g., retroviral safety) than that required for other cell types. But how susceptible is the cell line to viral contamination?

There are a couple of ways of answering this question. One way is to examine, in an empirical fashion, the susceptibility of the cell type to productive infection by model exogenous viruses. This type of study has been conducted at least three times over the past decades by different investigators. Wiebe and coworkers (In: Advances in Animal Cell Biology and Technology for Bioprocesses. Great Britain, 1989; 68-71) examined over 45 viruses from 9 virus families for ability to infect CHO-K1 cells, using immunostaining and cytopathic effect to detect infection. Only 7 of the viruses (Table 1) were capable of infecting the cells. Poiley and coworkers (In Vitro Toxicol. 4: 1-12, 1991) followed with a similar study in which 9 viruses from 6 families were evaluated for ability to infect CHO-K1 cells as detected by cytopathic effect, hemadsorption, and hemagglutination. This study did not add any new viruses to the short list (Table 1). The most recent study was conducted by Berting et al. This study involved 14 viruses from 12 families. The viruses included a few known to have contaminated CHO cell-derived biologics in the past two decades, and therefore did add some new entities to the list in Table 1. Still, the list of viruses that are known to replicate in CHO cells is relatively short.



Chinese hamster cells possess an endogenous retrovirus which expresses its presence in the form of retroviral particles, however these particles have been consistently found to be non-infectious for cells from other animals, including human cells. This endogenous retrovirus therefore does not present a safety threat (Dinowitz et al. Dev. Biol. Stand. 76:210–207, 1992).

A second way of looking at the question of viral susceptibility of CHO cells is to examine the incidence and types of reported viral contaminations of manufacturing processes employing CHO cell substrates. This subject has been reviewed a number of times, most recently by Berting et al. The types of viral contaminants fill a fairly short list (Table 2). In most cases, the contaminations have been attributed to the use of a contaminated animal-derived raw material, such as bovine serum.

Sources: Rabenau et al.1993; Garnick 1996; Oehmig et al., 2003; Nims Dev. Biol. 123:153-164, 2006; Nims et al., 2008; Genzyme 2009..

Considering the frequency with which CHO cell substrates have been used in biologics production, this history of viral contamination is remarkably sparse. This is further testament to the overall safety of this particular cell substrate.






Thursday, May 6, 2010

Epizootic hemorrhagic disease virus: a future troublemaker?


Epizootic hemorrhagic disease virus (EHDV) is a double-stranded RNA virus of family Reoviridae, genus Orbivirus. This is a non-enveloped virus of approximately 60-80 nm size. This arbovirus is transmitted by a biting midge of genus Culicoides, and is closely related to another Orbivirus, the bluetongue virus. Two serotypes are endemic to cattle in North America (EHDV-1 and EHDV-2); the infections caused tend to be subclinical (asymptomatic) and therefore may go undetected.

Infections in cattle are more prevalent in areas of widespread infection within the local deer population. As shown in the figure below, the geographic distribution of infection of deer populations with EHDV and bluetongue virus includes areas within the high plains and mountain states in which bovine serum production is high (Utah, Kansas, etc.).

From Daniel Mead, Risk of Introduction of New Vector-borne Zoonoses

There have been recent outbreaks of epizootic hemorrhagic disease in cattle in Indiana (2006) as well as other states; in Israel (2006); and in Turkey (2007).

Basis of Concern: EHDV has been isolated previously from a biologics manufacturing process employing a Chinese hamster ovary (CHO) cell substrate (Rabenau et al. Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 21, 207-214, 1993). The infection was presumed, but not proven, to originate from use of a contaminated bovine serum in the manufacturing process.

Regulatory Expectations. EHDV is not mentioned specifically in 9CFR 113.47 (Detection of extraneous viruses by the fluorescent antibody technique as a virus of concern for raw materials of bovine origin), although this regulation requires testing for the closely related bluetongue virus. EHDV would be expected to cause cytopathic effects in Vero cells, one of the detector cells used in the 9CFR 113.47 assay, therefore this assay should detect the virus in grossly contaminated bovine sera.

Mitigating Risk. Elimination of animal-derived materials (esp. bovine sera) from the manufacturing process should reduce the risk of experiencing this virus. If this is not possible, treatment of the sera should be considered. Gamma-irradiation of the frozen serum at the dosages normally used should be effective, judging from results obtained with REO virus, another member of the family Reoviridae (Gauvin, 2009).

Conclusions. EHDV has been found previously to contaminate a biologics manufacturing process employing a CHO-cell substrate. It is therefore a virus of concern for the biopharmaceutical industry. Risk of infection of biological products with EHDV through use of bovine-derived materials such as bovine sera may increase in the event of future outbreaks of this disease in cattle from serum-producing regions of North America or Australia. Risk may be mitigated through implementation of gamma-irradiation of bovine sera and of viral purification processes capable of removing and inactivating non-enveloped viruses such as MMV and REO.